Monday, February 7, 2022

Research is funded by five-year, $2.29 million grant from the National Institute of Neurological Disorders and Stroke.

Investigator(s): Lina R. Nih, PhD

LOS ANGELES (February 2, 2022) — The Lundquist Institute’s investigator Lina R. Nih, PhD,  and her colleagues at Penn State have received a five-year, $2.29 million grant from the National Institute of Neurological Disorders and Stroke — an institute within the National Institutes of Health — to explore the use of injectable porous biomaterials to target post-stroke immune response and promote new blood vessel and axon formation, processes known as angiogenesis and axonogenesis, respectively, at the site of the stroke.

Tuesday, January 4, 2022

The Lundquist Institute float in 2022 Rose Parade called “Impositive” to celebrate its 70th Anniversary.

Investigator(s): The Lundquist Institute

The Lundquist Institute participated in this past weekend’s Tournament of Roses Parade in celebration of its 70th Anniversary. The float’s theme Impositive means having optimism in the face of seemingly impossible odds. Impositivity propels the Institute forward as it continues its long history of making incredible groundbreaking discoveries and innovations that impact the world.

Monday, December 6, 2021

The Lundquist Institute will have a float in the 2022 Rose Parade called “Impositive” to celebrate its 70th Anniversary.

Investigator(s): The Lundquist Institute

The Lundquist Institute will have a float in the 2022 Rose Parade called “Impositive” to celebrate its 70th Anniversary. The float is sponsored by Impositivity Media and Emmaus Life Sciences and will feature riders whose lives have been saved by groundbreaking research conducted at the Institute. The Lundquist Investigators responsible for the life-saving therapies, Dr. Emil Kakkis and Dr. Yutaka Niihara, will also be riding on the float along with their former patients and Institute PhD students.

Friday, November 19, 2021

The study examines performance of the EyeArt AI system for detecting eyes with more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR).

Investigator(s): Eli Ipp, MD

The Lundquist Institute’s Investigator Eli Ipp, MD, and a multi-center team of investigators have evaluated the performance of the EyeArt AI system in a study published in JAMA Open Network. Dr. Ipp and his co-investigators found that the accuracy of the EyeArt AI system was high in detecting mtmDR (sensitivity 96% and specificity 88%) and vtDR (sensitivity 97% and specificity 90%).

Friday, November 19, 2021

Ataxia Telangiectasia (A-T) Is a Devastating Disorder in Children Characterized by a Severe Loss of Motor Coordination (Ataxia), Increased Cancer Susceptibility, Immunodeficiency, and Premature Death

Investigator(s): Paul Mathews, PhD

The Lundquist Institute’s investigators have developed a critically needed mouse model of Ataxia Telangiectasia (A-T), a currently untreatable, rare childhood disorder that results in a severe and progressive loss of motor coordination and premature death by 30 years of age. The disorder is caused by recessive genetic mutations in the A-T mutated (ATM) gene that prevent the production of an important DNA repair pathway protein referred to as ATM.

Friday, November 5, 2021

The Lundquist Institute’s Male Contraceptive Efficacy Trial has received an additional $3 million from the National Institutes of Health (NIH) to expand its work and recruit 120+ more couples.

The Lundquist Institute’s Male Contraceptive Efficacy Trial has received an additional $3 million from the National Institutes of Health (NIH) to expand its work and recruit 120+ more couples. This NIH funding will bring the total number of couples involved in the study to over 400.

Friday, September 24, 2021

The CIRM Grant Will Support Stem Cell Training and Research for the Institute’s PhD Students, Postdoctoral Fellows and Clinical Fellows

Investigator(s): The Lundquist Institute

LOS ANGELES (September 24, 2021) — The Lundquist Institute (TLI) announced that it has received a generous $5 million, 5-year grant from the California Institute for Regenerative Medicine (CIRM) that will allow its PhD students, postdoctoral fellows and clinical fellows to pursue careers in stem cell biology and regenerative medicine.

Wednesday, August 18, 2021

Convalescent plasma from blood donors who have recovered from COVID-19 does not prevent disease in acutely ill, high-risk patients with COVID-19.

LOS ANGELES — The Lundquist Institute announced that, in a new study published today in The New England Journal of Medicine, its Investigators and research colleagues at other institutions have found that passive immunization by infusion of COVID-19 convalescent plasma is not a viable strategy to reduce the severity of illness. Plasma from recovered patients who have already developed antibodies to SARS-CoV-2 is often the most readily available source of antibodies early in epidemics or emerging infections.

Tuesday, August 3, 2021
Investigator(s): The Lundquist Institute

LOS ANGELES — BioLabs LA at The Lundquist Institute, a co-working and incubator facility for high-potential bioscience start-ups, has reached 100% capacity ahead of schedule. This critical milestone demonstrates the strong demand for entrepreneurial startup opportunities in the bioscience sphere in Los Angeles. 

Monday, May 31, 2021

Paper in Nature Genetics: Genome-wide Meta-Analysis Shows That Research into Different Ancestries Leads to Better Results and Better Care

Investigator(s): Jerome I Rotter, MD

LOS ANGELES — Today The Lundquist Institute announced that its investigators contributed data from several studies, including data on Hispanics, African-Americans and East Asians, to the international MAGIC collaboration, composed of more than 400 global academics, who conducted a genome-wide association meta-analysis led by the University of Exeter. Now published in Nature Genetics, their findings demonstrate that expanding research into different ancestries yields more and better results, as well as ultimately benefitting global patient care.